Patents Examined by Lester L. Lee
  • Silica gels for controlling insect pests
    Patent number: 5135750
    Abstract: Specific inorganic silica gels are used as an adsorbent drying agent for controlling insect pests in a structure. When it is too humid in the structure, the silica gels adsorb moisture. On the other hand, when it is too dry in the structure, the silica gels supply moisture. The silica gels thus create the environment where household insect pests cannot survive. Moreover, by exposing invading insect pests to silica-gel particles, the pests' tissues are physiologically decayed, and the population density of the insect pests is decreased. Insect pests in the structure can by thus controlled using the silica gels.
    Type: Grant
    Filed: March 8, 1991
    Date of Patent: August 4, 1992
    Assignee: Fuji-Davison Chemical Ltd.
    Inventor: Yoshito Nakashima
  • Method for preparing a pharmaceutical composition in the form of microparticles
    Patent number: 5134122
    Abstract: A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.
    Type: Grant
    Filed: July 20, 1990
    Date of Patent: July 28, 1992
    Assignee: Debiopharm S.A.
    Inventor: Piero Orsolini
  • CRF analog conjugates
    Patent number: 5132111
    Abstract: Agonists and antagonists of rCRF are disclosed that exhibit good binding affinity to CRF receptors. One exemplary agonist is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser- Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met- Ala-Arg-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg- Leu-Leu-Leu-Glu-Glu-Ala-NH.sub.2. In the agonists, one or more of the first five N-terminal residues may be deleted or may be substituted by a peptide up to 10 amino acids long. A number of other substitutions may also be made throughout the chain. Similar peptides which function as CRF antagonists are created by deleting the first 7, 8 or 9 N-terminal residues. These analogs are coupled to a cytotoxin, such as gelonin, by a dialdehyde or the like, e.g., glutaraldehyde. The conjugates may be used to eliminate CRF Target Cells, and thus to regulate secretion of ACTH, .beta.-lipotropin and the like.
    Type: Grant
    Filed: April 11, 1990
    Date of Patent: July 21, 1992
    Assignee: The Salk Institute for Biological Studies
    Inventors: Wylie W. Vale, Jr., Jean E. F. Rivier, Jeffrey Schwartz
  • Anticoagulant/surfactant rodenticidal compositions and method
    Patent number: 5132321
    Abstract: Rodenticidal compositions comprising an anticoagulant type rodenticide in combination with a fluorosurfactant of the amphoteric, anionic or cationic type, optionally admixed with a cereal grain bait, and a method of killing rodents by oral administration of such compositions.
    Type: Grant
    Filed: September 5, 1989
    Date of Patent: July 21, 1992
    Assignee: Sterling Drug Inc.
    Inventor: Garland G. Corey
  • Hypothalamic polypeptides with adenylate cyclase stimulating activity
    Patent number: 5128242
    Abstract: The present invention relates to peptides having adenylate cyclase stimulating activity. The peptides all have at least the sequence His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr- Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-.
    Type: Grant
    Filed: June 19, 1989
    Date of Patent: July 7, 1992
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Akira Arimura, Atsuro Miyata
  • CCK analogs with appetite regulating activity
    Patent number: 5128448
    Abstract: The invention is directed to novel CCK analogs wherein Tryptophan and/or Phenylalamine are substituted with a radical which provides enhanced appetite suppressant activity to the peptide.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: July 7, 1992
    Assignee: Hoffman-La Roche Inc.
    Inventors: Waleed Danho, David J. Nelson, Gary L. Olson, Shian-Jan Shiuey, Jefferson W. Tilley, Rolf Wagner
  • Synthetic peptide antagonists of neurokinin A, salts thereof and respective preparation processes
    Patent number: 5128447
    Abstract: A synthetic peptide corresponding to the following formula:X--Asp--Y--DTrp--Val--DTrp--Z--K--NH.sub.2where:X=H, Arg, DArg, Lys, DLys, Thr, DThrY=Tyr, Trp, DTrp, Ser, MetZ=Trp, DTrpK=Arg, Phe, DTrp, Tyr, Metand pharmaceutically acceptable salts thereof with organic and inorganic acids as competitive antagonists against neurokinin A (NK-2 receptor).
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: July 7, 1992
    Assignee: A. Menarini Industrie Farmaceutiche Riunite S.r.l.
    Inventors: Paolo Rovero, Vittorio Pestellini, Carlo A. Maggi, Riccardo Patacchini, Paolo Santicioli, Sandro Giuliani, Alberto Meli
  • Melanocyte-stimulating hormone inhibitor and external preparation containing the same
    Patent number: 5126327
    Abstract: A melanocyte-stimulating hormone inhibitor has an amino acid sequence represented by the following formula [I], [II] or [III] in the molecule:--His--Ser--Arg--Trp-- [I]--Trp--Arg--Ser--His-- [II]--Leu--Ala--Cys--Ala--Arg-- [III]wherein His, Ser, Arg, Trp, Leu, Ala and Cys represent L-- or D-histidine, serine, arginine, tryptophan, leucine, alanine and cysteine residues, respectively. The melanocyte-stimulating hormone inhibitor and an external preparation to be applied to the skin which contains the inhibitor prevent or cure the symptoms of chloasmata and freckles caused by an excess production of melanin by enhanced melanocyte function.
    Type: Grant
    Filed: March 22, 1990
    Date of Patent: June 30, 1992
    Assignee: Lion Corporation
    Inventors: Takuji Takeuchi, Chikara Sato, Kenkichi Oba, Keikichi Sugiyama
  • Pancreatic secretory tryspin inhibitor and variants thereof produced by a recombinant host therefore and pharmaceutical use thereof
    Patent number: 5126322
    Abstract: The present invention relates to a peptide having essentially the amino acid sequence of pancreatic secretory trypsin inhibitor (PSTI). The present invention also relates to variants of such peptide wherein one or more of the amino acids in the original sequence are replaced by other amino acids. These peptides show an advantageously modified specificity in their inhibotory action. A method of preparation of the peptides and their pharmaceutical use is also described.
    Type: Grant
    Filed: April 16, 1991
    Date of Patent: June 30, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: John Collins, Helmut Blocker, Ronald Frank, Friedhelm Maywald, Hans Fritz, Wolfgang Bruns
  • Methods of improved skin care and the treatment of dermatological conditions
    Patent number: 5124313
    Abstract: The present invention provides methods for treating or preventing various dermatological conditions in humans, such as dry, cracked or damaged skin resulting from exposure to sunlight (ultraviolet radiation) and wind, aging effects, general skin dryness, e.g., deficient moisture content, and mild acne. These methods comprise applying an effective amount of a composition to the affected target area, the composition comprising a retinyl palmitate-polypeptide complex of apparent molecular weight of from about 5,000 to about 7,000 daltons, and an isoprenoid compound, e.g., a carotenoid such as beta-carotene.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: June 23, 1992
    Inventors: Hans A. Schaeffer, Geoffrey J. Brooks
  • Pharmaceutical compositions containing amylin
    Patent number: 5124314
    Abstract: The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: June 23, 1992
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventor: Garth J. S. Cooper
  • Immunosuppressive cyclosporin analogs with modified amino acids at position-8
    Patent number: 5122511
    Abstract: New immunosuppressive cyclosporin analogs are disclosed consisting of [dehydro-Ala].sup.8 cyclosporins and derived therefrom cyclosporins having a sulfur containing amino acid at position-8.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: June 16, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Arthur A. Patchett, David Taub, Robert T. Goegelman
  • Insulinotropic hormone
    Patent number: 5120712
    Abstract: A fragment of glucagon-like peptide I (GLP-1) has been found to be an insulinotropic hormone. This insulinotropic hormone comprises amino acid residues 7-37 of GLP-1. The insulinotropic hormone is useful as a potential therapy for Diabetes Mellitus.
    Type: Grant
    Filed: June 1, 1990
    Date of Patent: June 9, 1992
    Assignee: The General Hospital Corporation
    Inventor: Joel Habener
  • Synthetic polypeptide with laminin activity
    Patent number: 5120828
    Abstract: A polypeptide having the following formula is provided: arg-ile-gln-asn-leu-leu-lys-ile-thr-asn-leu-arg-ile-lys-phe-val-lys; which can bind heparin and promote cellular adhesion.Medical devices such as prosthetic implants, percutaneous devices and cell culture substrates coated with a composition including the polypeptide are also provided.
    Type: Grant
    Filed: May 8, 1989
    Date of Patent: June 9, 1992
    Assignee: Regents of the University of Minnesota
    Inventor: Aristidis S. Charonis
  • Metal-peptide compositions
    Patent number: 5120831
    Abstract: There is provided metal-peptide compositions for use as stimulating agents for hair growth in warm-blooded animals. Methods for stimulating the growth of hair in warm-blooded animals are also disclosed. The methods utilize a stimulating effective amount of the metal-petide composition or a pharmaceutical preparation containing the metal-peptide composition.
    Type: Grant
    Filed: November 13, 1989
    Date of Patent: June 9, 1992
    Assignee: ProCyte Corporation
    Inventor: Loren R. Pickart
  • Hydrophobic attachment site for adhesion peptides
    Patent number: 5120829
    Abstract: The invention provides a method of attaching peptides containing a biologically active site, for example RGD-containing adhesion peptides, to a solid surface through a hydrophobic domain, and peptides so attached. The hydrophobic domain can contain either hydrophobic amino acids, such as leucine, valine, isoleucine or phenylalanine, or fatty acids, such as, for example, myristic acid, palmitic acid, arachidic acid or other fatty acids. Additionally, spacers, such as amino acids, between the hydrophobic domain and the biologically active domain can improve the presentation of the biologically active site. Specific peptides of the invention includeGRGDSPASSKG.sub.4 RL.sub.6 RNH.sub.2 ;GRGDSPASSKS.sub.3 RL.sub.6 RNH.sub.2 ;andGRGDSPASSKSSKRL.sub.6 RNH.sub.2.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: June 9, 1992
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, Cyril J. Honsik, Lisa B. Dreisbach
  • Inhibitory peptides against .alpha.-2, .beta.-1 mediated mg.sup.++ dependent adhesion of platelets to collagen
    Patent number: 5120830
    Abstract: Novel short peptides are disclosed which are selected from the group consisting of GPAGKDGEAGAQG and fragments thereof containing the minimal sequence Ala Gly Glu Ala. These peptides have inhibitory activity against .alpha..sub.2 .beta..sub.1 -mediated Mg.sup.++ -dependent adhesion of platelets to collagen.
    Type: Grant
    Filed: October 25, 1990
    Date of Patent: June 9, 1992
    Assignee: Washington University
    Inventor: Samuel A. Santoro
  • Biologically active polypeptides based on transforming growth factor-.beta.
    Patent number: 5118791
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta.molecules in which from about 1 to 10 amino acid residues have been delected, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn -Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: June 2, 1992
    Assignee: Genentech, Inc.
    Inventors: John P. Burnier, George J. Cianciolo
  • Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
    Patent number: 5118669
    Abstract: The following oligopeptides containing -Asp-Gly- or -Asp-Ser- are synthesized:H-Asp-Gly-Lys-OHH-Ser-Asp-Gly-Lys-OHH-Asp-Ser-Asp-Gly-Lys-OHH-Ala-Asp-Ser-Asp-Gly-Lys-OHThe oligopeptides have antiallergic, vasodilating and immunoregulating activities and are very useful for treating allergic symptons.
    Type: Grant
    Filed: September 25, 1990
    Date of Patent: June 2, 1992
    Assignee: Hitachi Chemical Co., Ltd.
    Inventors: Keiichi Noguchi, Noriya Ohta, Daisuke Irie, Katsurou Matsuo, Kouhei Hirano, Asako Tokunaga, Fumio Ishikawa
  • Anti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof
    Patent number: 5118665
    Abstract: Compositions and methods for enhancing or restoring the resistance of a warm blooded animal to oxidative or inflammatory damage caused be release of reactive oxygen species by certain immune cells and other physiological processes are disclosed. The compositions include metal:peptide and metal:peptide:chelating agent complexes.
    Type: Grant
    Filed: February 9, 1990
    Date of Patent: June 2, 1992
    Assignee: ProCyte Corporation
    Inventor: Loren R. Pickart